Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (821-830 of 842) with videos related to

Pageof 85
Sort By:
Trials|October 15, 2013
Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B)Ian Paterson, George A Wells, Justin A Ezekowitz, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
The Canadian Journal of Cardiology|October 19, 2025
Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%)Sean Virani, Shelley Zieroth, Natasha Aleksova, et al.
The New England Journal of Medicine|August 30, 2011
Apixaban versus warfarin in patients with atrial fibrillationChristopher B Granger, John H Alexander, John J V McMurray, et al.
The Canadian Journal of Cardiology|February 1, 2014
The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization, Gordon W Moe, Justin A Ezekowitz, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
The Canadian Journal of Cardiology|December 24, 2014
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implicationsGordon W Moe, Justin A Ezekowitz, Eileen O'Meara, et al.
Circulation|January 5, 2022
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and SexAnthony P Carnicelli, Hwanhee Hong, Stuart J Connolly, et al.
European Heart Journal|June 5, 2020
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Stefan D Anker, Javed Butler, Muhammad Shahzeb Khan, et al.
The Canadian Journal of Cardiology|November 8, 2017
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart FailureJustin A Ezekowitz, Eileen O'Meara, Michael A McDonald, et al.
Pageof 85

Showing results (821-830 of 842) with videos related to

Sort By:
Pageof 85
Trials|October 15, 2013
Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B)Ian Paterson, George A Wells, Justin A Ezekowitz, et al.
Lancet (London, England)|April 10, 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsJaved Butler, Sanjiv J Shah, Mark C Petrie, et al.
The Canadian Journal of Cardiology|October 19, 2025
Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%)Sean Virani, Shelley Zieroth, Natasha Aleksova, et al.
The New England Journal of Medicine|August 30, 2011
Apixaban versus warfarin in patients with atrial fibrillationChristopher B Granger, John H Alexander, John J V McMurray, et al.
The Canadian Journal of Cardiology|February 1, 2014
The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization, Gordon W Moe, Justin A Ezekowitz, et al.
The New England Journal of Medicine|April 8, 2024
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesMikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, et al.
The Canadian Journal of Cardiology|December 24, 2014
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implicationsGordon W Moe, Justin A Ezekowitz, Eileen O'Meara, et al.
Circulation|January 5, 2022
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and SexAnthony P Carnicelli, Hwanhee Hong, Stuart J Connolly, et al.
European Heart Journal|June 5, 2020
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Stefan D Anker, Javed Butler, Muhammad Shahzeb Khan, et al.
The Canadian Journal of Cardiology|November 8, 2017
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart FailureJustin A Ezekowitz, Eileen O'Meara, Michael A McDonald, et al.
Pageof 85